- Title:
- Misoprostol treatment for early pregnancy loss: an international survey
- Journal:
- Reproductive BioMedicine Online
- Author(s):
- Yossi Mizrachi1,2, Gon Shoham2, Milton Leong3, Ron Sagiv1,2, Eran Horowitz1,2, Arieh Raziel1,2, ,Ariel Weissman1,2
- Author(s) affiliation:
- 1Department of Obstetrics and Gynecology, The Edith Wolfson Medical Center, PO Box 5, Holon 58100, Israel;
2Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel
3The IVF Clinic, Hong Kong, China
- Short description:
- What is the global variability in misoprostol treatment for the management of early pregnancy loss (EPL)?.
- Link to the journal
Abstract taken from PubMed
- Research question:
- What is the global variability in misoprostol treatment for the management of early pregnancy loss (EPL)?
- Design:
- An international web-based survey of fertility specialists and obstetrics and gynaecology clinicians was conducted between August and November 2020. The survey consisted of 16 questions addressing several aspects of misoprostol treatment for EPL.
- Results:
- Overall, 309 clinicians from 80 countries participated in the survey, of whom 67.3% were fertility specialists. Nearly one-half (47.9%) of the respondents let the patient choose the first line of treatment (expectant management, misoprostol treatment or surgical aspiration) according to her own preference. The 248 respondents who administer misoprostol in their daily practice were asked further questions; 59.7% of them advise patients to take the medication at home. The most common dose and route of administration is 800 µg administered vaginally. Only 28.6% of participants use mifepristone pretreatment. Variation in the timing of the first follow-up visit after misoprostol administration was wide, ranging from 24 h to 1 week in most clinics. In case of incomplete expulsion, only 42.3% of the respondents routinely administer a second dose. The timing of the final visit and the definition of successful treatment also differed greatly among respondents.
- Conclusions:
- There is large variability in the use of misoprostol for the management of EPL. High-quality research is necessary to examine several aspects of the treatment. Particularly, the timing and effectiveness of a second dose administration and the criteria to decide on treatment failure or success deserve more research in the future.
- Link to the paper on PubMed
